Merck snares NovaCardia in $350M buyout

Merck has bolstered its cardiovascular pipeline with a deal to buy NovaCardia for $350 million in cash. For Merck, the acquisition marks another step down its five-year plan to restructure the company. Buying up new therapies in development is a key part of that effort, and the competition for acquisitions has been steadily driving up valuations in the biotech world. NovaCardia has a drug--KW-3902--in late-stage studies for congestive heart failure.

"This acquisition continues to deliver on our strategy of targeted acquisitions in areas of unmet medical need in the therapeutic areas of strategic importance for Merck, such as cardiovascular diseases," said Richard Kender, vice president of business development and corporate licensing at Merck.

- check out Merck's announcement
- here's the AP report on the buyout

Related Articles:
Analysts cheer signs of turnaround at Merck. Report
Merck touts reorganization effort. Report
NovaCardia, Quark Biotech file for $86M IPOs. Report
NovaCardia pockets $48M in second round. Report

Suggested Articles

With case counts surging and top officials infected, the U.K. is joining the testing for Gilead Sciences' much-hyped antiviral candidate remdesivir.

By redeploying staff, the FDA thinks it can respond to COVID-19-related requests and review protocols within 24 hours of receipt.

The partners leveraged their proximity to the initial outbreak and experience with SARS and MERS to build up a library of neutralizing antibodies.